Trump to visit Fed on Thursday amid Powell feud, renovation probe
SEATTLE—In a recent move, Mallick Parag, Chief Scientist and a key figure at Nautilus Biotechnology, Inc. (NASDAQ:NAUT), purchased a substantial amount of the company’s common stock amid the company’s 74% share price decline over the past year. According to a filing with the Securities and Exchange Commission, Parag acquired a total of 13,500 shares over two transactions.
The purchases took place on May 8 and May 12, with 12,000 shares bought at a weighted average price of $0.7323 per share and an additional 1,500 shares at an average price of $0.7317 per share. These transactions amounted to a total investment of $9,885. According to InvestingPro data, the company maintains a strong balance sheet with more cash than debt, though it’s currently trading below its Fair Value.
Following these acquisitions, Parag’s direct ownership in Nautilus Biotechnology increased to 20,493,392 shares. The purchases were executed within a price range of $0.7058 to $0.7520 for the first transaction and $0.7229 to $0.7334 for the second, according to the filing details. InvestingPro subscribers have access to 10 additional key insights about NAUT, including detailed analysis of its financial health and growth prospects. Get the complete picture with the comprehensive Pro Research Report, available exclusively on InvestingPro.
In other recent news, Nautilus Biotechnology reported its first-quarter 2025 earnings, revealing a smaller-than-expected loss with an EPS of -$0.13, surpassing the forecast of -$0.15. The company highlighted a reduction in operating expenses by 13% year-over-year, contributing to a net loss of $16.6 million, down from $18.7 million in the prior year. Nautilus ended the quarter with a cash position of $193 million, extending its cash runway through 2027. The company continues to focus on its proteomics platform, planning a launch in late 2026, and anticipates forming its first partnership in the academic or nonprofit sector within the first half of 2025.
Analysts from firms like Morgan Stanley (NYSE:MS) and Goldman Sachs inquired about potential partnerships and supply chain strategies, with Nautilus indicating ongoing discussions with partners in the pharma, nonprofit, and academic sectors. The company is also monitoring supply chain resilience, particularly regarding tariffs, and has flexibility in sourcing materials from various locations, including the U.S. Nautilus emphasized that its strategic focus remains on demonstrating the capabilities of its proteomics platform, with less emphasis on immediate revenue generation from partnerships.
The company’s efforts in cost management and innovation in proteomics have been well-received, with Nautilus planning to submit a manuscript summarizing its verification and validation work in the coming months. Nautilus’s CEO, Sujal Patel, reiterated the company’s commitment to pioneering a new approach in proteomics, which holds the potential to overcome current limitations in protein measurement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.